These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7756795)

  • 41. Surfactant treatment for neonatal respiratory disorders other than respiratory distress syndrome.
    Alkan S; Ozer EA; Ilhan O; Sutcuoglu S; Tatli M
    J Matern Fetal Neonatal Med; 2015 Jan; 28(2):131-3. PubMed ID: 24716748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome.
    Wang JY; Yeh TF; Lin YC; Miyamura K; Holmskov U; Reid KB
    Thorax; 1996 Sep; 51(9):907-13. PubMed ID: 8984701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical characteristics and risk factors of very low birth weight and extremely low birth weight infants with bronchopulmonary dysplasia: multicenter retrospective analysis].
    Jiangsu Multicenter Study Collaborative Group for Breastmilk Feeding in Neonatal Intensive Care Units
    Zhonghua Er Ke Za Zhi; 2019 Jan; 57(1):33-39. PubMed ID: 30630229
    [No Abstract]   [Full Text] [Related]  

  • 45. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants.
    Göpel W; Kribs A; Härtel C; Avenarius S; Teig N; Groneck P; Olbertz D; Roll C; Vochem M; Weller U; von der Wense A; Wieg C; Wintgens J; Preuss M; Ziegler A; Roth B; Herting E;
    Acta Paediatr; 2015 Mar; 104(3):241-6. PubMed ID: 25474712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inherited disorders of neonatal lung diseases.
    Yurdakök M
    Turk J Pediatr; 2004; 46(2):105-14. PubMed ID: 15214737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noninvasive Support: Does It Really Decrease Bronchopulmonary Dysplasia?
    Wright CJ; Polin RA
    Clin Perinatol; 2016 Dec; 43(4):783-798. PubMed ID: 27837759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Surfactant and respiratory distress syndrome.
    Milner AD
    Turk J Pediatr; 1996; 38(1):37-43. PubMed ID: 8819619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2004; (3):CD003063. PubMed ID: 15266470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant.
    Whitsett JA; Hull WM; Luse S
    Pediatrics; 1991 Apr; 87(4):505-10. PubMed ID: 2011428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between Hemoglobin Levels in the First 3 Days of Life and Bronchopulmonary Dysplasia in Preterm Infants.
    Duan J; Kong X; Li Q; Hua S; Zhang S; Feng Z; Zhang X
    Am J Perinatol; 2016 Aug; 33(10):998-1002. PubMed ID: 27120476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The morbidities of extremely preterm and extremely low birth weight infants during hospitalization].
    ;
    Zhonghua Er Ke Za Zhi; 2015 May; 53(5):334-40. PubMed ID: 26080662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome.
    Tegtmeyer FK; Möller J; Richter A; Wilken B; Fischer T
    Eur Respir J; 1994 Feb; 7(2):260-4. PubMed ID: 8162977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant.
    Bose C; Corbet A; Bose G; Garcia-Prats J; Lombardy L; Wold D; Donlon D; Long W
    J Pediatr; 1990 Dec; 117(6):947-53. PubMed ID: 2246698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The surfactant system protects both fetus and newborn.
    Hallman M
    Neonatology; 2013; 103(4):320-6. PubMed ID: 23736009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chorioamnionitis alters the response to surfactant in preterm infants.
    Been JV; Rours IG; Kornelisse RF; Jonkers F; de Krijger RR; Zimmermann LJ
    J Pediatr; 2010 Jan; 156(1):10-15.e1. PubMed ID: 19833352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surfactant protein A in the course of respiratory distress syndrome.
    Stevens PA; Schadow B; Bartholain S; Segerer H; Obladen M
    Eur J Pediatr; 1992 Aug; 151(8):596-600. PubMed ID: 1505580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perinatal prevention of bronchopulmonary dysplasia.
    Greenough A; Ahmed N
    J Perinat Med; 2013 Jan; 41(1):119-26. PubMed ID: 23096098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bubble nasal CPAP, early surfactant treatment, and rapid extubation are associated with decreased incidence of bronchopulmonary dysplasia in very-low-birth-weight newborns: efficacy and safety considerations.
    Friedman CA; Menchaca RC; Baker MC; Rivas CK; Laberge RN; Rios EH; Haider SH; Romero EJ; Eason EB; Fraley JK; Woldesenbet M
    Respir Care; 2013 Jul; 58(7):1134-42. PubMed ID: 23106970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bronchopulmonary dysplasia].
    Clément A
    Rev Mal Respir; 1996 Jul; 13(3):243-9. PubMed ID: 8765916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.